Syphilis serology in human immunodeficiency virus patients: a need to redefine the VDRL test cut-off for biological false-positives
The interpretation of non-treponemal and treponemal specific serological tests in a population where syphilis and human immunodeficiency virus (HIV) are endemic may not be straightforward (Augenbraun et al., 1994) . The VDRL test for syphilis screening may, under certain circumstances, yield positive results in patients not infected with Treponema pallidum (biological false-positive reaction). In contrast, treponemal antibody tests such as the T. pallidum particle agglutination (TPPA) test have a high specificity, but in HIV-infected patients false-negative reactions have been reported (Erbelding et al., 1997; Gwanzura et al., 1999) . A retrospective study was carried out to test the adequacy of VDRL as a screening test for the diagnosis of syphilis in HIV patients and to estimate the prevalence of HIV-syphilis coinfection in the North Indian population. Accordingly, serum samples collected from 2671 HIV-seropositive patients (January 2002 -April 2008 were tested by VDRL using a standard method (Young, 1996) . A positive VDRL test was considered to indicate syphilis. TPPA (Fujibro, Japan) testing was then performed on reactive VDRL sera.
Of the 2671 serum samples tested, 134 (5.01 %) were found to be reactive by the VDRL test. Of the 134 sera reactive in the VDRL test, 100 gave a VDRL titre of ,8 dilutions and 34 showed a VDRL titre of ¢8 dilutions. Sixty-one TPPA-positive samples gave titres of ,8 in the VDRL test (Table 1 ). The biological false-positivity rate in this cohort of HIV patients was 39/2671 (1.46 %).
Our study shows that the cut-off of 1 : 8 in the VDRL test cannot be depended upon in HIV co-infection because in cases where the TPPA test was positive, only 61 % were reactive by the VDRL test in ,8 dilutions. These results indicate that the cut-off for biological false-positives should be reevaluated in the HIV-syphilis co-infected population as a substantial number of truly infected patients might be missed if the cut-off is taken to be ,1 : 8. The TPPA test was also found to be positive in only 55.8 % of sera which were reactive by the VDRL test in .8 dilutions. This means that in HIV-infected patients, a titre of .1 : 8 might not necessarily indicate true infection. There may be another explanation for TPPA negativity in some patients at least. It has been seen that, occasionally, an infected patient, especially one with an underlying immune dysfunctional state, e.g. co-HIV infection, will have a true-positive non-specific test with a false-negative specific treponemal test (Erbelding et al., 1997) . Thakar et al. (1996) reported total agreement between the TPPA test and VDRL test with a titre of 1 in 16 and above indicating that the VDRL titres above 1 in 8 should be considered as true-reactives to minimize the biological false-positive reactions. Our study, however, did not find such correlation between high VDRL titres and TPPA positivity. Therefore, our study questions the accuracy of the current cutoff for biological false-positives in the widely used VDRL screening test in the HIV-syphilis co-infected patient and reemphasizes the need to use an additional confirmatory T. pallidum specific serological test to accurately diagnose syphilis in these patients. 
